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S U M M A R Y
Background: The South African Electronic Drug-Resistant Tuberculosis Register (EDRweb) is the national
database of registered drug-resistant tuberculosis (DR-TB) cases.
Methods: This study was a retrospective, de-identiﬁed secondary analysis of EDRweb patients initiating
treatment for rifampicin-resistant TB (January 2009 to September 2011). The relative risks of death and
treatment success were estimated using modiﬁed Poisson regression with robust error estimation.
Results: Seventeen thousand six hundred and ninety-seven cases of DR-TB were registered and met the
inclusion criteria; 52.0% (n = 9207) were male and the median age was 35 years (interquartile range 27–
43 years). Of the 9419 cases with HIV infection (53.2%), 7157 (76.0%) were on antiretroviral therapy.
Most had undergone previous TB treatment (76.5%, n = 13 531). Multidrug-resistant TB was the most
common diagnosis, at 80.6% (n = 14 272). No treatment outcome was available for 6934 patients (39.2%).
For patients with outcomes, 4227 (39.4%) were successfully treated, 2987 (27.8%) died, 2533 (23.7%)
were lost to follow-up, and 996 (9.3%) failed. Second-line drug resistance was the strongest predictor of
death during DR-TB treatment; extensively drug-resistant TB patients were more likely to have died
during treatment (adjusted relative risk 2.63, 95% conﬁdence interval 2.45–2.84).
Conclusions: Testing for second-line drug resistance at initiation of DR-TB treatment can identify
patients most at risk of treatment failure and death and most in need of individualized treatment.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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According to the World Health Organization (WHO) Global
Tuberculosis Report for 2014, South Africa was among the
10 highest drug-resistant tuberculosis (DR-TB) burden countries
in the world when ranked by estimated burden of multidrug-
resistant (MDR) TB cases.1 In terms of the absolute number of cases
diagnosed as rifampicin (RIF)-resistant TB, South Africa ranked
fourth behind only China, India, and Russia.1 The 2011 South* Corresponding author.
E-mail address: kschnipp@gmail.com (K. Schnippel).
http://dx.doi.org/10.1016/j.ijid.2015.09.002
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).African guidelines for the decentralization and deinstitutionaliza-
tion of MDR-TB treatment have resulted in an increasing number of
patients receiving second-line treatment for DR-TB each year. The
number of patients who successfully completed DR-TB treatment
was reported as 45% of the 2011 cohort.1
Since 2009, South Africa has maintained an electronic case
register for DR-TB patients, the Electronic Drug-Resistant Tuber-
culosis Register (EDRweb). In order to inform policy and practice
for improved DR-TB outcomes, patient and treatment character-
istics reported within the EDRweb were analysed to determine
predictors of treatment success or mortality during DR-TB
treatment for patients registered from January 1, 2009 to
September 30, 2011.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
K. Schnippel et al. / International Journal of Infectious Diseases 39 (2015) 89–94902. Methods
A retrospective, de-identiﬁed secondary analysis of the
routinely reported EDRweb database was conducted. TB and DR-
TB are notiﬁable diseases in South Africa, and the National TB
Programme (NTP) maintains national case registration databases.
The EDRweb has been the electronic case registration database for
the South African NTP since 2009; however, the paper-based
registers were used for reporting to the WHO until 2012. A census
of patients registered in the EDRweb from January 1, 2009 up to
September 30, 2011, with follow-up until September 30, 2013, was
exported for analysis (n = 22 152).
2.1. DR-TB treatment guidelines and case deﬁnitions 2009–2011
MDR-TB is deﬁned as DR-TB that is resistant to RIF and isoniazid
(INH). Although drug-sensitive TB can be diagnosed based upon
clinical indications, South African guidelines require bacteriologi-
cal laboratory conﬁrmation of MDR-TB. At initiation of second-line
treatment and if not improving clinically, a patient who has MDR-
TB is tested for further anti-TB drug resistance. Resistance to RIF
and INH plus any ﬂuoroquinolone (FLQ) and any second-line
injectable drug (SLID) is deﬁned as extensively drug-resistant
(XDR) TB. Resistance to RIF and INH and either a FLQ or a SLID is
referred to as preXDR-TB. Until new guidelines were issued in
2011,2 most South African DR-TB patients were treated as
inpatients at specialized, provincial-level M/XDR-TB treatment
centres.2 South African NTP guidelines prior to 2011 indicated that
patients with at least MDR-TB should be hospitalized for 6 months
or until they achieved culture conversion, deﬁned as two
consecutive months with culture-negative sputa.3
The Xpert MTB/RIF test for the diagnosis of TB and RIF resistance
was not available within the South African NTP during the study
period. Patients at high risk of having DR-TB as a result of being a
contact of a person with DR-TB, or due to failure to smear convert
during TB treatment, were targeted for DR-TB testing. Diagnosis
relied mainly on phenotypic drug sensitivity testing (DST) of
culture isolates. The National Health Laboratory Service (NHLS)
rolled out line probe assay (LPA) genotypic testing on culture
isolates from 2009 to 2011,4 and the results from LPA were
reported for RIF and INH if available. DST was performed through
the NHLS specialized laboratories for a panel of ﬁrst-line drugs: RIF,
INH, ethambutol (EMB), and streptomycin (SM). If at least MDR-TB,
then a panel of second-line drugs would be tested: kanamycin
(KM), oﬂoxacin (OFX), and ethionamide (ETO). Each panel of DST
cultures took 6 to 12 weeks for results.
Patients with RIF resistance or MDR-TB were treated with a
standardized regimen,3 consisting of two phases. The 6-month
intensive phase (usually hospitalized) included daily dosing of a
SLID, KM, or amikacin (AM) and four additional oral drugs: OFX,
EMB or ETO, terizidone (TZD), and pyrazinamide (PZA). The
continuation phase of treatment included continuation of the
regimen for 18 months following culture conversion, with the
exception of the SLID. Patients with XDR-TB or documented
resistance to either a FLQ or SLID (preXDR) could access
individualized regimens including the SLID capreomycin, moxi-
ﬂoxacin (MFX), para-aminosalicylic acid (PAS), or clofazimine.
Outcomes of DR-TB treatment were assigned at the end of
treatment (typically 24 months) and were deﬁned at the time as:
‘cured’, i.e. completed treatment and culture-negative for ﬁve
consecutive months in the last year of treatment; ‘completed’, i.e.
completed treatment but did not meet the deﬁnition of cured;
‘died’, i.e. death due to any cause while on DR-TB treatment;
‘default’ (lost to treatment follow-up), i.e. treatment interrupted
for two or more consecutive months; ‘failure’, i.e. two or more
positive cultures out of the ﬁve consecutive cultures taken in theﬁnal year of treatment; or ‘still on treatment’ at the time of report.3
Treatment success was deﬁned as the sum of patients who were
either cured or completed treatment.
2.2. HIV treatment guidelines 2009–2011
In April 2010, the South African guidelines for antiretroviral
therapy (ART) were updated to indicate that all M/XDR-TB
patients, regardless of CD4 count, were eligible for ART initiation
and should be fast-tracked for initiation.5 Prior to this (the
2004 guidelines), only patients who had a CD4 count of <200 cells/
mm3 were eligible and there was uncertainty as to the timing of
initiation of ART for TB patients.6
2.3. EDRweb and data extraction
De-duplication and cleaning of the register was done as per the
standard policies and procedures of the NTP prior to export.
Follow-up data were censored at September 30, 2013. All patient
records included in the study had at least 24 months of follow-up
time. All patient identiﬁers were removed during the export
process. Patients were excluded if they had no record of initiating
DR-TB treatment within EDRweb (n = 3743). Patients who were
reported to have only mono-resistant TB and no laboratory RIF
result (i.e., mono-INH-resistant, n = 462), who were reported as
transfer-in (n = 223), or who were missing a DR-TB diagnosis
(n = 27), were also excluded from the analysis. Thus, only patients
with at least RIF-resistant TB were included in the analysis.
Patient and treatment characteristics analysed included age,
sex, history of previous TB treatment, year of registration, TB foci
(extrapulmonary or pulmonary), reported drug resistance, diag-
nosis of drug-resistant TB, HIV status, baseline smear and culture
results, and DR-TB treatment. Age at registration was categorized
as <15, 15–29, 30–44, 45–59, and 60 years and older.
Each patient could have multiple DST result sets reported. Each
entry was numbered, with the month of testing reported (month
0 for treatment initiation, month 1 after 1 month of treatment, etc.),
date of sputum collection, laboratory specimen number, and the
drugs that had a resistant outcome. Drugs that were tested that had
a sensitive, non-viable isolate, or contaminated result, were not
reported. For the analysis, month 0 reports were deﬁned as baseline.
Patient diagnosis was reported in the dataset as one of MDR-TB,
mono- or poly-resistant DR-TB, or XDR-TB. For the analysis, if a
patient was diagnosed as MDR-TB and had a reported DST result of
resistance to a FLQ or a SLID, this was categorized as preXDR-TB.
Each patient could have multiple HIV tests reported. Each entry
was numbered, with the date of testing and results. Additionally,
HIV status was reported as a separate variable, presumably to
incorporate patients with known HIV status who were not tested
and counselled for HIV during DR-TB treatment. Any report of the
patient being HIV-infected was recorded as the patient being HIV-
infected. If no tests were reported as HIV-positive and there was at
least one HIV report of being HIV-negative, the patient was recorded
as HIV-negative. ART started was a ‘yes/no’ variable. Patients were
categorized as HIV-negative, HIV-positive on ART, HIV-positive not
on ART or ART status unknown, or HIV status unknown.
Each patient had multiple monthly sputum smear microscopy
and sputum culture tests reported – up to 40 entries. Smear status
was reported as negative or positive, but no speciﬁc grading (i.e.
scant, +, ++, +++) was given. There was also a report of an ‘initial’ smear
and culture result (deﬁned as being taken prior to referral to the DR-
TB unit) and a ‘baseline’ smear and culture result (deﬁned as the
sputum specimen taken on admission to the DR-TB unit). A positive
smear result in the baseline, initial, or month 0 report was deﬁned as
smear-positive at baseline for the analysis; the same deﬁnition and
method was applied to establish baseline culture results.
Table 1
Baseline descriptive characteristics of RIF-resistant TB patients registered in
EDRweb from January 1, 2009 to September 30, 2011
Characteristic Count Proportion %
All patients (N = 17 697)
Gender
Male 9207 52.0%
Female 8406 47.5%
Missing 84 0.5%
Age, years Median: 35 IQR: 27–43
<15 526 3.0%
15–29 5171 29.2%
30–44 8068 45.6%
45–59 3396 19.2%
60+ 536 3.0%
HIV status
HIV-infected 9419 53.2%
HIV-negative 4770 27.0%
HIV status unknown, missing 3508 19.8%
Antiretroviral therapy
On ART (before or during DR-TB) 7157 76.0%
Not on ART 918 9.7%
ART status missing 1344 14.3%
Previously treated for TB
New patient 4161 23.5%
History of TB treatment 13 531 76.5%
TB foci
Pulmonary TB 15 910 89.9%
Extrapulmonary TB 178 1.0%
Not reported, missing 1609 9.1%
Sputum smear microscopy at baselinea
AFB-positive 8076 45.6%
AFB-negative 6286 35.5%
Not reported or error 3335 18.8%
Sputum culture at baselinea
MTB-positive 12 386 70.0%
Negative 1828 10.3%
Not reported or contaminated 3483 19.7%
RIF, rifampicin; TB, tuberculosis; EDRweb, South African Electronic Drug-Resistant
Tuberculosis Register; IQR, interquartile range; ART, antiretroviral therapy; DR-TB,
drug-resistant tuberculosis; AFB, acid-fast bacilli; MTB, Mycobacterium tuberculosis.
a A positive smear result in the baseline, initial, or month 0 report was deﬁned as
smear-positive at baseline for the analysis; the same deﬁnition and method was
applied to establish baseline culture results.
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Figure 1. Patients included in the analysis of baseline characteristics and reported
outcomes.
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that may have been prescribed for either the intensive or
continuation phase, or because of a regimen change during
treatment. Doses, the duration of treatment, and the reasons for
treatment changes are not reported within EDRweb.
One treatment outcome is retained in EDRweb with one
outcome date; the outcome may be changed after cohort reporting
(e.g., 24-month outcomes reported to the WHO). The treatment
outcome date reﬂected the date of reporting or assignment of the
outcome at 24 months. For death, treatment failure, and loss to
follow-up, the outcome date was deﬁned as the date the patient
was last at the facility, not necessarily the date of the event.
2.4. Statistical analysis
All analyses were conducted in Stata SE version 13 (StataCorp.,
College Station, TX, USA). Patient and treatment characteristics
were recorded using the median and interquartile range (IQR) for
continuous variables, and the frequency and proportion for
categorical variables. Predictors of treatment outcome (either
treatment success or death) were estimated using modiﬁed
Poisson regression with robust standard errors to produce relative
risks (risk ratios, or RR);7 these were reported with the
corresponding 95% conﬁdence intervals (CI). The univariate and
adjusted (multivariate) results are presented.
2.5. Ethics
Ethical approval for this de-identiﬁed, retrospective secondary
analysis of routinely reported patient-level data was received from
the Human Research Ethics Committee of the University of the
Witwatersrand.
3. Results
3.1. DR-TB patient characteristics
Patient characteristics are summarized in Table 1. Seventeen
thousand six hundred and ninety-seven cases of DR-TB were
registered between January 2009 and September 2011, met the
inclusion criteria, and were included in the baseline analysis
(Figure 1). Approximately half of the patients were male (52.0%),
and the median age was 35 years. Of the 9419 patients with
reported HIV infection (53.2%), 7157 (76.0%) were on ART.
Less than half of the patients were smear microscopy-positive
at ‘baseline’ (n = 8076, 45.6%), although HIV-uninfected patients
were more likely to be smear microscopy-positive (52.8%) than
HIV-infected patients (45.0%) (Chi-square difference of propor-
tions, p < 0.000). A positive sputum culture at baseline was
reported for 70.0% (n = 12 386) of patients; 10.3% were culture-
negative at baseline and 19.7% of patients were either missing
culture results or culture was contaminated.
3.2. DR-TB diagnosis and treatment
MDR-TB was the most common diagnosis in the cohort, at 80.6%
(n = 14 272), including 4.3% (n = 617) of patients with preXDR-TB;
9.5% of patients were RIF-mono-resistant and 9.8% of patients had
XDR-TB (Table 2).
Just over half of the MDR-TB patients (56.3%) were reported as
receiving at least the standard regimen (KM/AM, OFX, ETO, TZD,
PZA). Most (89.9%) XDR-TB patients were on individualized
regimens containing PAS (79.2%), capreomycin (73.8%), and/or
MFX (49.9%). Almost all patients, regardless of diagnosis, received a
SLID (93.9%), FLQ (92.7%), ETO (91.6%), and PZA (95.1%).3.3. DR-TB treatment outcomes
Treatment outcomes reported in EDRweb as of September
2013 are presented in Table 3. No outcome was reported for 39.2%
Table 2
Diagnosis and treatment of RIF-resistant TB patients in EDRweb (January 1, 2009 to
September 30, 2011)
Characteristic Count
(N = 17 697)
Proportion %
DR-TB diagnosis
RIF mono-resistant TB 1671 9.5%
MDR-TB (resistant to RIF and INH) 14 272 80.6%
MDR-TB without second-line resistance 13 655 77.2%
PreXDR-TB SLID 391 2.2%
PreXDR-TB FLQ 226 1.3%
XDR-TB (MDR-TB plus SLID and FLQ) 1741 9.8%
Year of registration
2009 5457 30.8%
2010 6613 37.4%
2011 (censored at September 30, 2011) 5627 31.8%
DST resistance reported
Rifampicin (RIF)-resistant 15 442 87.3%
Isoniazid (INH)-resistant 13 514 76.4%
Ethambutol (EMB)-resistant 1563 8.8%
Streptomycin (SM)-resistant 3803 21.5%
Kanamycin (KM)-resistant 662 3.7%
Amikacin (AM)-resistant 1046 6.5%
Oﬂoxacin (OFX)-resistant 1313 7.4%
Second-line treatmenta
Amikacin (AM) 2780 15.7%
Kanamycin (KM) 12 333 69.7%
Capreomycin (CM) 1653 9.3%
Any second-line injectable drug (SLID) 16 625 93.9%
Oﬂoxacin (OFX) 14 555 82.3%
Moxiﬂoxacin (MFX) 1909 10.8%
Any ﬂuoroquinolone (FLQ) 16 410 92.7%
Ethambutol (EMB) 11 576 65.4%
Para-aminosalicylic acid (PAS) 1838 10.4%
Terizidone (TZD) 12 976 73.3%
Pyrazinamide (PZA) 16 835 95.1%
Ethionamide (ETO) 16 215 91.6%
RIF, rifampicin; TB, tuberculosis; EDRweb, South African Electronic Drug-Resistant
Tuberculosis Register; DR-TB, drug-resistant tuberculosis; MDR-TB, multidrug-
resistant tuberculosis; INH, isoniazid; XDR-TB, extensively drug-resistant tubercu-
losis; SLID, second-line injectable drug; FLQ, ﬂuoroquinolone; DST, drug sensitivity
testing.
a Only standard regimen or drugs reported to be used in more than 1000 patients
are listed; reported drugs not listed above: clofazimine (n = 114, 0.6%), ciproﬂoxacin
(n = 326, 1.8%), isoniazid (n = 762, 4.3%), rifampicin (n = 186, 1.1%), streptomycin
(n = 70, 0.3%), levoﬂoxacin (n = 16, 0.1%), prothionamide (n = 26, 0.1%), clarithro-
mycin (n = 125, 0.7%), amoxicillin (n = 115, 0.6%), and cycloserine (n = 17, 0.1%).
K. Schnippel et al. / International Journal of Infectious Diseases 39 (2015) 89–9492(n = 6934) of all patients in the cohort. Patients who initiated
treatment in 2011 were less likely to have treatment outcomes
(p < 0.05).
For patients with outcomes, treatment success was the most
common outcome, at 39.4% (cured 27.5% (n = 2695) and completed
treatment 11.8% (n = 1262)). Unsuccessful outcomes were the
following: 27.8% died, 23.7% were lost to follow-up, and 9.3% failedTable 3
Treatment outcomes as of September 30, 2013 for RIF-resistant TB patients in EDRweb
Outcome All patients RIF-resistanta
All patients n = 17 697 n = 1684 
All outcomes n = 10 763 (60.8%) n = 818 (48.6%) 
Cured 2965 (27.5%) 276 (33.7%) 
Completed 1262 (11.8%) 94 (11.5%) 
Successful 4227 (39.4%) 370 (45.2%) 
Died 2987 (27.8%) 157 (19.2%) 
Lost to follow-up 2553 (23.7%) 241 (29.5%) 
Treatment failure 996 (9.3%) 50 (6.1%) 
Missing outcomec n = 6934 (39.2%) n = 866 (51.4%) 
RIF, rifampicin; TB, tuberculosis; EDRweb, South African Electronic Drug-Resistant Tub
drug-resistant tuberculosis; INH, isoniazid; DST, drug sensitivity testing.
a Includes both cases that were conﬁrmed mono-RIF-resistant and cases that were d
b Case registration reported as having MDR-TB and having reported DST resistance 
c Cases reported as being ‘still on treatment’ were categorized as missing the ‘ﬁnal’ treatment. For XDR-TB patients with outcomes (n = 1076), 60.8%
(n = 654) died during treatment. XDR-TB treatment success across
the three years of case registration was 12.7% (n = 137).
3.4. Relative risk of death during DR-TB treatment
Second-line drug resistance was the strongest predictor of
death during DR-TB treatment (Table 4). Patients who had XDR-TB
(adjusted RR (aRR) 2.63, 95% CI 2.45–2.84) and those who had
preXDR-TB FLQ (aRR 1.56, 95% CI 1.23–1.98) or preXDR-TB SLID
(aRR 1.63, 95% CI 1.38–1.94) were all more likely than those who
did not have documented second-line drug resistance to have died
during treatment.
Compared to patients known to be HIV-negative, patients who
were HIV-infected and not on ART or with ART status unknown,
were nearly twice as likely to die (aRR 1.90, 95% CI 1.69–2.14).
Those who were HIV-infected on ART and with unknown HIV
status had similar risks of mortality – aRR 1.54 (95% CI 1.41–1.69)
and aRR 1.66 (95% CI 1.48–1.86), respectively.
Baseline smear positivity (aRR 1.47, 95% CI 1.36–1.59) and prior
TB treatment (aRR 1.16, 95% CI 1.06–1.27) were both associated
with a higher relative risk of mortality. Patients aged <15 years
were 36% less likely to die (aRR 0.64, 95% CI 0.48–0.87), while
patients aged 60 years were more likely to die (aRR 1.83, 95% CI
1.56–2.15) compared to patients aged 45–59 years. No statistically
signiﬁcant differences in mortality were associated with sex,
treatment with FLQ or SLID, or year of treatment initiation.
3.5. Relative risk of successful DR-TB treatment
The absence of reported second-line drug resistance was the
strongest predictor of successful treatment (Table 5). Patients who
had XDR-TB (aRR 0.31, 95% CI 0.26–0.36) and those who had
preXDR SLID (aRR 0.48, 95% CI 0.38–0.61) or preXDR FLQ (aRR 0.51,
95% CI 0.37–0.69) were all signiﬁcantly less likely to have either
completed treatment or been cured.
HIV-infected patients on ART were as likely to be successfully
treated as HIV-negative patients (aRR 0.98, 95% CI 0.92–1.03). HIV-
infected patients not on ART or ART status missing were 19% less
likely than HIV-negative patients to have a successful outcome
(aRR 0.81, 95% CI 0.74–0.88).
Males were less likely to successfully complete treatment
compared to females (aRR 0.83, 95% CI 0.79–0.87). Patients who
were smear microscopy- and culture-positive at baseline were less
likely to successfully complete treatment compared to those with
negative results (aRR 0.81, 95% CI 0.77–0.85, and aRR 0.80, 95% CI
0.75–0.85, respectively). Children <15 years old were 1.32 times
more likely to have successful outcomes than patients aged 45–59
years (95% CI 1.18–1.48)., by diagnosis category
MDR-TB PreXDR-TBb XDR-TB
n = 13 655 n = 617 n = 1741
n = 8433 (61.8%) n = 436 (70.7%) n = 1076 (61.8%)
2528 (30.0%) 61 (14.0%) 100 (9.3%)
1104 (13.1%) 27 (6.2%) 37 (3.4%)
3720 (44.1%) 88 (20.2%) 137 (12.7%)
2008 (23.8%) 168 (38.5%) 654 (60.8%)
2109 (25.0%) 58 (13.3%) 145 (13.5%)
684 (8.1%) 122 (28.0%) 140 (13.0%)
n = 5222 (38.2%) n = 181 (29.3%) n = 665 (38.2%)
erculosis Register; MDR-TB, multidrug-resistant tuberculosis; XDR-TB, extensively
iagnosed RIF-resistant but with INH sensitivity not conﬁrmed.
to either a ﬂuoroquinolone or a second-line injectable.
outcome.
Table 5
Relative risk of treatment success during DR-TB treatment, by patient and
treatment characteristicsa
RR 95% CI Adjusted
RRb
95% CI
Male 0.86 0.82–0.90 0.83 0.79–0.87
Treatment included SLID 1.00 0.89–1.12 0.92 0.83–1.03
Treatment included FLQ 1.12 1.01–1.24 0.92 0.83–1.02
Second-line drug resistance
RIF or MDR (no
second-line resistance)
Ref. Ref.
Resistant to SLID 0.45 0.35–0.57 0.48 0.38–0.61
Resistant to FLQ 0.49 0.36–0.66 0.51 0.37–0.69
XDR-TB 0.29 0.25–0.34 0.31 0.26–0.36
History of TB treatment 0.84 0.80–0.88 0.91 0.86–0.96
HIV-status
HIV-negative Ref. Ref.
HIV-infected, on ART 1.03 0.97–1.08 0.98 0.92–1.03
HIV-infected, not on ART 0.86 0.79–0.94 0.81 0.74–0.88
HIV unknown 0.98 0.91–1.05 0.80 0.89–1.03
Smear microscopy positive
at baselinec
0.73 0.69–0.76 0.81 0.77–0.85
Sputum culture positive
at baselinec
0.68 0.64–0.73 0.80 0.75–0.85
Age group, years
<15 1.56 1.40–1.75 1.32 1.18–1.48
15–29 0.91 0.85–0.98 0.85 0.79–0.91
30–44 0.97 0.91–1.03 0.94 0.88–1.00
45–59 Ref. Ref.
60+ 0.84 0.72–0.98 0.84 0.72–0.97
Registration year
2009 Ref. Ref.
2010 0.98 0.93–1.04 1.00 0.95–1.07
2011 0.92 0.87–0.98 0.95 0.90–1.01
DR-TB, drug-resistant tuberculosis; RR, relative risk; CI, conﬁdence interval; SLID,
second-line injectable drug; FLQ, ﬂuoroquinolone; RIF, rifampicin; MDR, multi-
drug-resistant; XDR-TB, extensively drug-resistant tuberculosis; ART, antiretroviral
therapy.
a Relative risk (risk ratio) calculated using Poisson regression with robust
standard errors.
b Adjusted for all other factors in the table.
c A positive smear result in the baseline, initial, or a month 0 report was deﬁned
as smear-positive at baseline for the analysis; the same deﬁnition and method was
applied to establish baseline culture results.
Table 4
Relative risk of death during DR-TB treatment, by patient and treatment
characteristicsa
RR 95% CI Adjusted
RRb
95% CI
Male 0.95 0.89–1.01 0.98 0.92–1.05
Treatment included SLID 0.88 0.77–1.00 1.02 0.88–1.19
Treatment included FLQ 0.68 0.62–0.75 0.91 0.81–1.01
Second-line drug resistance
RIF or MDR (no
second-line resistance)
Ref. Ref.
Resistant to SLID 1.69 1.45–1.96 1.63 1.38–1.94
Resistant to FLQ 1.53 1.23–1.89 1.56 1.23–1.98
XDR-TB 2.59 2.44–2.75 2.63 2.45–2.84
History of TB treatment 1.25 1.16–1.36 1.16 1.06–1.27
HIV-status
HIV-negative Ref. Ref.
HIV-infected, on ART 1.51 1.40–1.64 1.54 1.41–1.69
HIV-infected, not on ART 1.70 1.53–1.88 1.90 1.69–2.14
HIV unknown 1.68 1.52–1.85 1.66 1.48–1.86
Smear microscopy positive
at baselinec
1.58 1.46–1.70 1.47 1.36–1.59
Sputum culture positive
at baselinec
1.48 1.28–1.71 1.16 1.00–1.35
Age group, years
<15 0.65 0.50–0.85 0.64 0.48–0.87
15–29 0.80 0.73–0.87 0.78 0.71–0.87
30–44 0.92 0.85–1.00 0.85 0.78–0.93
45–59 Ref. Ref.
60+ 1.47 1.28–1.68 1.83 1.56–2.15
Registration year
2009 Ref. Ref.
2010 1.05 0.97–1.13 1.04 0.96–1.13
2011 1.08 1.00–1.17 1.08 0.98–1.18
DR-TB, drug-resistant tuberculosis; RR, relative risk; CI, conﬁdence interval; SLID,
second-line injectable drug; FLQ, ﬂuoroquinolone; RIF, rifampicin; MDR, multi-
drug-resistant; XDR-TB, extensively drug-resistant tuberculosis; ART, antiretroviral
therapy.
a Relative risk (risk ratio) calculated using Poisson regression with robust
standard errors.
b Adjusted for all other factors in the table.
c A positive smear result in the baseline, initial, or a month 0 report was deﬁned
as smear-positive at baseline for the analysis; the same deﬁnition and method was
applied to establish baseline culture results.
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moderate in impact (aRR 0.91, 95% CI 0.86–0.96). Treatment with
either a SLID or a FLQ and year of registration were not statistically
signiﬁcant predictors of success.
4. Discussion
Since 2009, South Africa has maintained the EDRweb for routine
reporting of all DR-TB patients treated within the South African
NTP. The 17 697 cases of DR-TB registered between January 1,
2009 and September 30, 2011 represent one of the largest cohorts
of DR-TB patients on treatment in the world.
A 2009 systematic review of global MDR-TB treatment outcomes
reported a pooled treatment success rate of 62%;8 DR-TB treatment
success was reported by the WHO as 48% for the 2011 global cohort.1
For the same year, South Africa reported a treatment success rate of
45%.1 Because of censoring in the data extract, updating of treatment
outcomes since reporting, and veriﬁcation of reporting against paper
reports, the EDRweb export analysed here cannot be compared
directly to the WHO reported cohorts. However, having information
about the patient and treatment characteristics can increase our
understanding of the outcomes reported.
Approximately half of the patients in EDRweb were reported as
HIV-infected (53.2%), with most HIV-infected patients being on
ART (76.0%). HIV-infected patients not on ART were nearly two
times more likely to die than HIV-negative patients (aRR 1.90). A
low CD4 count (especially 100 cells/mm3) is a known predictor ofmortality for persons who are HIV-infected,9 but only 5.4% of HIV-
infected patients had a CD4 count reported in EDRweb. In 2010,
South Africa changed its ART guidelines based upon evidence that
early ART initiation during TB treatment could reduce mortality.5,6
The change in guidelines occurred during the period analysed here,
and the non-signiﬁcant difference in risk of success for patients
who are on ART compared to the HIV-negative (aRR 0.98) found in
this study is encouraging. Because the duration on ART and
baseline CD4 are important clinical indicators for persons with
HIV, improved capturing of this information in the national
database could improve the management of these patients.
The strongest predictor of mortality in this cohort was not HIV
infection, but resistance to the most effective second-line drugs in
the treatment regimen: preXDR SLID (aRR 1.63), preXDR FLQ (aRR
1.56), or both (XDR-TB, aRR 2.63). This ﬁnding should add weight
to recommendations proposing that all DR-TB patients be tested
for additional resistance at treatment initiation and highlights the
need for new classes of second-line TB treatment.1
Patients initiating DR-TB treatment in 2011 in the South African
NTP had earlier access to ART,5 expanded access to rapid molecular
detection of INH and RIF resistance,4 and potential access to the
fourth-generation FLQ MFX.10 New guidelines issued in 2011 also
decentralized MDR-TB treatment,2 which meant that patients may
have been able to access appropriate treatment earlier.11 However,
the impact of these changes could not be detected in the EDRweb
data, which were censored at September 30, 2011. DR-TB
treatment registration in 2011 compared to 2009 was not a
K. Schnippel et al. / International Journal of Infectious Diseases 39 (2015) 89–9494signiﬁcant predictor of treatment success (aRR 0.95). The analysis
should be repeated with the complete 2011 cohort and 2012 cohort
before conclusions can be drawn regarding the impact of the
improvements in DR-TB diagnosis, treatment, and treatment
access introduced in 2011.
Many of the patient and treatment characteristics have
associations and relationships among themselves, e.g., HIV
infection was found to be associated with negative baseline smear
microscopy and DST for second-line drug resistance, which can
only be done if a patient has a positive baseline culture. Yet, the
adjusted model for both relative risk of mortality and treatment
success showed little difference to the unadjusted model. The
robustness of the relative risk for mortality for patients with
second-line drug resistance even when holding HIV status, sputum
smear status, treatment regimen, age, and sex constant, empha-
sizes the importance of this ﬁnding. Eleven percent (n = 1996) of
the cohort did not have any DST results reported within EDRweb.
An additional 61.3% of the cohort had reported resistance to only
INH and/or RIF. Expanding the reporting requirement to include
sensitive DST results would help us to identify those patients
within this 61.3% who were tested and were sensitive to second-
line drugs and how many never accessed second-line DST.
There are limitations to this study. This was a retrospective, de-
identiﬁed secondary cohort analysis of routinely reported data.
Reporting requirements were not necessarily designed to provide
information to answer research questions. Gaps in reporting could
not be addressed by ﬁle review or contacting patients. The missing
information on treatment outcome (39.2% of the cohort without a
treatment outcome) is the biggest limitation of the data. The
treating clinician is responsible for assigning outcomes; informa-
tion extracted from medical ﬁles and reported within EDRweb is
not sufﬁcient for outcomes to be assigned without additional
patient ﬁle review. Recognizing the high number of patients
without outcomes, the South African NTP has been leading a
process of training, guidelines, and data-cleaning.
Another possible limitation is the analysis of a de-identiﬁed
extract of EDRweb. Use of a unique patient identiﬁer was not
government policy during the period of analysis and therefore
duplicate registrations may have been included. However, treat-
ment sites were centralized at a provincial level and efforts are made
within the NTP standard reporting procedures to match patients
using names, addresses, and dates of birth; therefore duplication is
not likely to be a signiﬁcant source of bias in this cohort.
During the study period, the Xpert MTB/RIF test was not in use
in South Africa and testing for RIF resistance was not universal.
Patients with a history of TB treatment were prioritized for
resistance testing and this may have led to an over-estimation of
persons with prior TB as a proportion of persons with DR-TB in
South Africa. Analysis of cohorts initiated from 2013 after roll-out
of Xpert MTB/RIF as the initial TB diagnostic was complete, as well
as the results of the recently completed national TB drug resistance
surveillance, should better inform our understanding of whether
DR-TB is transmitted or acquired in this context.
Only patients who have initiated RIF-resistant DR-TB treatment
are routinely reported in EDRweb. A substantial proportion of
patients diagnosed during this period were not initiated on
treatment,12 and MDR-TB and XDR-TB with HIV co-infection have
been shown to have a high early mortality rate in this setting.13
Therefore, these ﬁndings can only be applied to patients who were
diagnosed and survived until treatment initiation, not to all
persons with DR-TB in South Africa.
In conclusion, the diagnosis of XDR-TB and reported resistance
to two effective classes of second-line TB drugs – the ﬂuoroqui-
nolones and second-line injectable drugs – are the strongest
predictors of mortality during DR-TB treatment and poor rates oftreatment success. Interventions targeted at identifying and
treating this additional resistance, such as universal testing of
all DR-TB patients for second-line drug resistance, the use of rapid
genotypic diagnostic tests to screen for second-line drug resis-
tance, and increased access to new classes of second-line TB
treatment (such as linezolid, bedaquiline, delamanid, and pre-
tomanid), could be effective in reducing mortality and improving
the rate of treatment success in South Africa’s National TB
Programme.
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